摘要
目的探究达可替尼(Dacomitinib)治疗表皮生长因子受体(EGFR)敏感突变型非小细胞肺癌(NSCLC)患者的临床效果。方法将收治的NSCLC患者112例分为对照组(n=56)和观察组(n=56),对照组采用吉非替尼治疗,观察组采用达可替尼治疗。通过临床疾病控制率(DCR)评价药物治疗NSCLC的近期疗效,通过第一次进展生存时间(PFS-1)以及第二次进展生存时间(PFS-2)评价药物治疗的远期疗效,同时记录治疗过程中皮疹、腹泻、恶心呕吐的发生情况以及转氨酶水平。结果观察组的DCR与对照组相比显著升高,差异具有统计学意义(P <0. 05),同时观察组的PFS-1以及PFS-2也显著延长(P <0. 05)。此外,2组患者的皮疹以及腹泻的等级评价无统计学意义(P> 0. 05),观察组的呕吐、腹泻以及转氨酶水平的毒性等级与对照组相比显著升高(P <0. 05)。结论达可替尼治疗EGFR敏感突变型非小细胞肺癌患者的临床效果显著,但是毒副作用较重。
Objective To survey clinical effect of Dacomitinib in non-small cell lung cancer( NSCLC) patients with epidermal growth factor receptor( EGFR) mutations and provide clinic base for the clinical application of the Dacomitinib. Methods All 112 NSCLC patients were randomly allocated to the control group( n = 56) and observation group( n = 56). The control group was treated with Gefitinib,while the observation group performed with Dacomitinib. After that,the short-term clinical efficacy was evaluated by the disease control rate( DCR). The Long-term clinical efficacy was tested by the first progression free survival( PFS-1) and the second progression free survival( PFS-2). The toxic and side effect were assessed by the common symptom including the rash,diarrhea,nausea and vomiting,and transaminase level. Results The DCR in the observation group had statistical meaning as compared with the control group( P < 0. 05). The PFS-1 and PFS-2 between observation group and control group had significant difference( P < 0. 05). Besides,the toxic grade of the rash and diarrhea between observation group and control group had no significant difference but not the nausea and vomiting,and transaminase level. Conclusion The clinical effect of dacomitinib in NSCLC patients with EGFR mutations is prominent while the toxic and side effect were heavier.
作者
肖会荣
马伟
马玲
XIAO Huirong;MA Wei;MA Ling(Department of Geriatrics,Wuzhong People's Hospital,Wuzhong 751100,China)
出处
《宁夏医学杂志》
CAS
2018年第12期1155-1157,共3页
Ningxia Medical Journal
关键词
非小细胞肺癌
达可替尼
吉非替尼
表皮生长因子受体
Non-small cell lung cancer
Dacomitinib
Gefitinib
Epidermal growth factor receptor
